JUNS JUPITER NEUROSCIENCES, INC.

Nasdaq jupiterneurosciences.com


$ 1.47 $ -0.01 (-0.67 %)    

Thursday, 23-Oct-2025 15:57:24 EDT
QQQ $ 611.70 $ 5.09 (0.84 %)
DIA $ 467.20 $ 1.51 (0.32 %)
SPY $ 672.21 $ 3.96 (0.59 %)
TLT $ 91.38 $ -0.63 (-0.68 %)
GLD $ 378.90 $ 1.51 (0.4 %)
$ 1.48
$ 1.47
$ 1.47 x 150
$ 1.70 x 10
$ 1.47 - $ 1.57
$ 0.51 - $ 19.51
74,708
na
49.11M
$ -0.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-18-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 12-23-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jupiter-neurosciences-launches-nugevia-mnd-to-boost-cognitive-health-using-resveratrol-and-novasol-curcumin

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuropro...

 jupiter-neurosciences-highlights-jotrol

JOTROL™ is currently advancing toward a Phase IIa trial in Parkinson's Disease, following breakthrough preclinical data in ...

 jupiter-neurosciences-unveils-nugevia-pwr-to-meet-demand-for-clinically-validated-longevity-supplements-commercial-availability-expected-in-fall-2025

PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfo...

 jupiter-neurosciences-commercially-launches-nugevia-first-consumer-products-roll-out-in-q3-2025

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's ev...

 jupiter-neurosciences-highlights-upcoming-milestones-in-shareholder-letter-including-lead-clinical-asset-jotrol-into-a-phase-2a-clinical-trial-in-parkinsons-disease

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of ...

 jupiter-neurosciences-enters-agreement-with-catalent-for-jotrol-softgel-production-for-phase-2a-parkinsons-clinical-trial

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION